Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CYP2C9*3 allelic variant and bleeding complications.

× No keyword cloud information.

19 in total

1. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.

Authors: A Holstein; A Plaschke; M Ptak; E-H Egberts; J El-Din; J Brockmöller; J Kirchheiner
Journal: Br J Clin Pharmacol Date: 2005-07 Impact factor: 4.335

2. The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.

Authors: Ahmed M L Bedewy; Salah A Sheweita; Mostafa Hasan Mostafa; Lamia Saeed Kandil
Journal: Indian J Hematol Blood Transfus Date: 2016-09-27 Impact factor: 0.900

Review 3. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.

Authors: Elena García-Martín; Carmen Martínez; José M Ladero; José A G Agúndez
Journal: Mol Diagn Ther Date: 2006 Impact factor: 4.074

4. Warfarin dose related to apolipoprotein E (APOE) genotype.

Authors: Hugo Kohnke; Kristina Sörlin; Göran Granath; Mia Wadelius
Journal: Eur J Clin Pharmacol Date: 2005-06-11 Impact factor: 2.953

5. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?

Authors: J H S You; F W H Chan; R S M Wong; G Cheng
Journal: Br J Clin Pharmacol Date: 2005-05 Impact factor: 4.335

Review 6. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors: Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal: Clin Pharmacokinet Date: 2008 Impact factor: 6.447

7. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.

Authors: Cong Ma; Yuxiao Zhang; Qiang Xu; Jie Yang; Yan Zhang; Lei Gao; Bin Xu; Hongjuan Wang; Yang Li; Caiyi Lu; Tong Yin
Journal: Int J Hematol Date: 2012-10-27 Impact factor: 2.490

8. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.

Authors: N A Limdi; G McGwin; J A Goldstein; T M Beasley; D K Arnett; B K Adler; M F Baird; R T Acton
Journal: Clin Pharmacol Ther Date: 2007-07-25 Impact factor: 6.875

9. The influence of co-treatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose.

Authors: Darja Herman; Igor Locatelli; Iztok Grabnar; Polona Peternel; Mojca Stegnar; Mitja Lainscak; Ales Mrhar; Katja Breskvar; Vita Dolzan
Journal: Eur J Clin Pharmacol Date: 2006-03-22 Impact factor: 2.953

10. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.

Authors: Masako Ohno; Akiko Yamamoto; Ayumu Ono; Genta Miura; Masanobu Funamoto; Yasuhiko Takemoto; Kinya Otsu; Yasushi Kouno; Tomoko Tanabe; Yuiko Masunaga; Shinpei Nonen; Yasushi Fujio; Junichi Azuma
Journal: Eur J Clin Pharmacol Date: 2009-07-07 Impact factor: 2.953